# mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms

> **NCT04393246** · PHASE2,PHASE3 · COMPLETED · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 454 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** EDP1815
- **DRUG:** Dapagliflozin
- **DRUG:** Ambrisentan
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT04393246
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-03
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-06-08
- **Target enrollment:** 454 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04393246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04393246, "mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04393246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*